# D-Serine for Enhancing Cognitive Retraining for the Treatment of Schizophrenia

> **NCT00237848** · PHASE3 · COMPLETED · sponsor: **Yale University** · enrollment: 72 (estimated)

## Conditions studied

- Schizophrenia
- Schizoaffective Disorder

## Interventions

- **DRUG:** D-serine
- **BEHAVIORAL:** Cognitive retraining

## Key facts

- **NCT ID:** NCT00237848
- **Lead sponsor:** Yale University
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-02
- **Primary completion:** —
- **Final completion:** —
- **Target enrollment:** 72 (ESTIMATED)
- **Last updated:** 2012-06-18

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00237848

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00237848, "D-Serine for Enhancing Cognitive Retraining for the Treatment of Schizophrenia". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT00237848. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*